Skip Navigation

Search By:

XX-XXX

Refine by:

14 Clinical Trials Found

Enrolling

A Randomized Multicenter Phase Ib/II study to assess the safety and immunological effect of chemoradiation therapy (CRT) in combination with MK-3475 (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer

The phase Ib / II trial studies the side effects of capecitabine and radiation therapy with or without pembrolizumab in treating participants with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from...

  • Phase: I/II
  • Trial ID: NCT02305186

Enrolling

A Randomized Phase 2 Study of Losartan and Nivolumab in Combination with FOLFIRINOX and SBRT in Localized Pancreatic Cancer.

This phase II trial studies how well losartan and nivolumab work in combination with combination chemotherapy and stereotactic body radiation therapy (SBRT) in treating patients with pancreatic cancer that has not spread to other parts of the body (localized). Losartan is a drug that is used to lower blood pressure. Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in...

  • Phase: II
  • Trial ID: NCT03563248

Not Enrolling

Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas (A021501)

This randomized phase II trial studies how well combination chemotherapy (mFOLFIRINOX) with or without hypofractionated radiation therapy before surgery works in patients with pancreatic cancer that can be removed by surgery. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of...

  • Phase: II
  • Trial ID: NCT02839343

Enrolling

Vitamin D Receptor Agonist Paricalcitol plus Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

This phase I / II trial studies the side effects and how well paricalcitol, gemcitabine hydrochloride, and nab-paclitaxel work in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Paricalcitol is a form of vitamin D that works by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor. Drugs used in chemotherapy,...

  • Phase: I/II
  • Trial ID: NCT03520790

Not Enrolling

Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients with Advanced Pancreatic Cancer

This phase Ib trial studies the side effects and best dose of ficlatuzumab when given together with gemcitabine hydrochloride and nab-paclitaxel in treating patients with pancreatic cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as ficlatuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells...

  • Phase: I
  • Trial ID: NCT03316599

Not Enrolling

Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together with Gemcitabine and nab-Paclitaxel with or without PD-1 Blocking Antibody (Nivolumab) in Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.

  • Phase: I/II
  • Trial ID: NCT03214250

Not Enrolling

A PHASE IIA, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF BL-8040 AND PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC PANCREATIC CANCER, THE COMBAT STUDY

This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL8040 / Pembrolizumab in combination with liposomal irinotecan (Onivyde®) / 5-fluorouracil / leucovorin (5-FU / LV) in subjects with metastatic pancreatic adenocarcinoma.

  • Phase: II
  • Trial ID: NCT02826486

Enrolling

A Phase 1b/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer)

A Phase Ib / II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior...

  • Phase: I/II
  • Trial ID: NCT03193190

Enrolling

Phase 2 Proof-of-Concept Trial Testing the PARP Inhibitor Niraparib in Patients with Pancreatic Cancer Harboring Deficiencies in Homologous Recombination DNA Repair

This phase II trial studies how well niraparib works in treating patients with pancreatic cancer with mutations in DNA repair genes that has spread to other places in the body (advanced or metastatic) or cannot be removed by surgery (unresectable). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • Phase: II
  • Trial ID: NCT03601923

Not Enrolling

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without Chemotherapy in Patients with Advanced Pancreatic Cancer

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

  • Phase: II
  • Trial ID: NCT03336216